{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-051002","form_type":"8-K","ticker":"XWEL","cik":"0001410428","company_name":"XWELL, Inc.","filed_at":"2025-05-20T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.202140+00:00","generated_at":"2026-05-20T23:51:20.556331+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"XWELL Q1 revenue falls to $7.0M; net loss $4.7M; CDC contract extended 3 years","bullets":["Revenue $7.0M, down 19% from $8.7M YoY; net loss attributable $4.7M vs $2.5M.","Cost of sales down 6% to $5.7M; operating expenses down 11% to $4.5M; operating loss $3.2M.","Closed $4M private placement (Series G preferred + warrants) in Jan 2025; cash $3.7M, marketable securities $7.3M, no debt.","Secured 3-year extension of CDC Traveler-based Genomic Surveillance Program (TGS) in March 2025.","Plans to acquire medical spas in Orlando, Dallas, Salt Lake City; new XWELL location at NYC Penn Station mid-2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-051002","json":"https://secwatch.observer/filing/0001104659-25-051002.json","markdown":"https://secwatch.observer/filing/0001104659-25-051002.md","text":"https://secwatch.observer/filing/0001104659-25-051002.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1410428/000110465925051002/0001104659-25-051002-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1410428/000110465925051002/tm2515209d2_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-20T23:51:20.556331+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}